Xianping Lu

Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma

Yue Shi, Mei Dong, Xiaoting Hong et al. · Annals of Oncology · 2015 · 396 citations

Medicine, Immunology, Oncology +11

Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity

Zhiqiang Ning, Zhibin Li, Michael Newman et al. · Cancer Chemotherapy and Pharmacology · 2011 · 294 citations

Medicine, Oncology, Pharmacology +13

Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial

Zefei Jiang, Wei Li, Xichun Hu et al. · The Lancet Oncology · 2019 · 267 citations

Medicine, Oncology, Pharmacology +14

Phase I study of chidamide (CS055/HBI-8000), a new histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas

Mei Dong, Zhiqiang Ning, Pu-yuan Xing et al. · Cancer Chemotherapy and Pharmacology · 2012 · 122 citations

Medicine, Oncology, Pharmacology +11

Naringenin and hesperetin, two flavonoids derived from <i>Citrus aurantium</i> up‐regulate transcription of adiponectin

Li Liu, Kun Zhang, Zhiqiang Ning et al. · Phytotherapy Research · 2008 · 121 citations

Life Sciences, Botany, Pharmacology +15